Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1426
{ "count": 24378, "next": "http://api.gregory-ms.com/articles/?format=api&page=1427", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1425", "results": [ { "article_id": 380812, "title": "Pathological cut-offs of global and regional brain volume loss in multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Volumetric MRI surrogate markers of disease progression are lacking. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To establish cut-off values of brain volume loss able to discriminate between healthy controls and MS patients. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> In total, 386 patients after first demyelinating event suggestive of MS (CIS), 964 relapsing-remitting MS (RRMS) patients, 63 secondary-progressive MS (SPMS) patients and 58 healthy controls were included in this longitudinal study. A total of 11,438 MRI scans performed on the same MRI scanner with the same protocol were analysed. Annualised percentage changes of whole brain, grey matter, thalamus and corpus callosum volumes were estimated. We investigated cut-offs able to discriminate between healthy controls and MS patients. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> At a predefined specificity of 90%, the annualised percentage change cut-off of corpus callosum volume (−0.57%) was able to distinguish between healthy controls and patients with the highest sensitivity (51% in CIS, 48% in RRMS and 42% in SPMS patients). Lower sensitivities (22%−49%) were found for cut-offs of whole brain, grey matter and thalamic volume loss. Among CIS and RRMS patients, cut-offs were associated with greater accumulation of disability. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> We identified cut-offs of annualised global and regional brain volume loss rates able to discriminate between healthy controls and MS patients. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458517742739", "published_date": "2017-11-16T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 149329, "given_name": "Maria Pia", "family_name": "Sormani", "ORCID": "http://orcid.org/0000-0001-6892-104X", "country": null }, { "author_id": 322818, "given_name": "Eva Kubala", "family_name": "Havrdova", "ORCID": "http://orcid.org/0000-0002-9543-4359", "country": null }, { "author_id": 241018, "given_name": "Dana", "family_name": "Horakova", "ORCID": null, "country": null }, { "author_id": 151316, "given_name": "Tomas", "family_name": "Uher", "ORCID": "http://orcid.org/0000-0003-3160-9022", "country": null }, { "author_id": 317884, "given_name": "Manuela", "family_name": "Vaneckova", "ORCID": "http://orcid.org/0000-0002-8784-7997", "country": null }, { "author_id": 322817, "given_name": "Jan", "family_name": "Krasensky", "ORCID": "http://orcid.org/0000-0002-5605-8821", "country": null }, { "author_id": 213444, "given_name": "Lukas", "family_name": "Sobisek", "ORCID": "http://orcid.org/0000-0001-8071-2005", "country": null }, { "author_id": 268747, "given_name": "Michaela", "family_name": "Tyblova", "ORCID": null, "country": null }, { "author_id": 304969, "given_name": "Jana", "family_name": "Volna", "ORCID": null, "country": null }, { "author_id": 273476, "given_name": "Zdenek", "family_name": "Seidl", "ORCID": null, "country": null }, { "author_id": 143256, "given_name": "Niels", "family_name": "Bergsland", "ORCID": "http://orcid.org/0000-0002-7792-0433", "country": null }, { "author_id": 147934, "given_name": "Michael G", "family_name": "Dwyer", "ORCID": "http://orcid.org/0000-0003-4684-4658", "country": null }, { "author_id": 143251, "given_name": "Robert", "family_name": "Zivadinov", "ORCID": "http://orcid.org/0000-0002-7799-1485", "country": null }, { "author_id": 150517, "given_name": "Nicola", "family_name": "De Stefano", "ORCID": "http://orcid.org/0000-0003-4930-7639", "country": "IT" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Pathological cut-offs", "global and regional brain volume loss", "multiple sclerosis" ], "doi": "10.1177/1352458517742739", "access": "restricted", "takeaways": " In total, 386 patients after first demyelinating event suggestive of MS (CIS), 964 relapsing-remitting MS (RRMS) patients, 63 secondary-progressive MS patients and 58 healthy controls were included in this longitudinal study . Annualised percentage changes of whole brain, grey matter, thalamus and corpus callosum volumes were estimated .", "categories": [] }, { "article_id": 380697, "title": "World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application", "summary": "<jats:sec><jats:title>Introduction:</jats:title><jats:p> The World Health Organization (WHO) publishes a biennial Essential Medicines List (EML) to assist governments in low-resource settings to prioritize their spending on medicines. Currently, no medicines on the EML have a multiple sclerosis (MS) indication. Multiple Sclerosis International Federation (MSIF) prepared an application for inclusion of MS disease-modifying therapies (DMTs) for the 2019 EML together with the regional Committees for Treatment and Research in Multiple Sclerosis (TRIMS) and the World Federation of Neurology. </jats:p></jats:sec><jats:sec><jats:title>Rationale:</jats:title><jats:p> The MSIF taskforce categorized 15 DMTs according to their efficacy and risk profiles to ensure the ability to treat as many different clinical scenarios as possible. Three DMTs were selected: glatiramer acetate, fingolimod, and ocrelizumab. </jats:p></jats:sec><jats:sec><jats:title>Outcome:</jats:title><jats:p> The WHO Expert Committee did not recommend the addition of any of the DMTs to the EML. They acknowledged the public health burden of MS, the need for effective and affordable MS medications, and the high volume of letters received in support of the application but requested a revised application. </jats:p></jats:sec><jats:sec><jats:title>Discussion:</jats:title><jats:p> Despite the negative outcome, the repeated recognition of MS as a global public health burden is sending a powerful message to governments globally that a range of affordable and good quality medications need to be available to health systems and people affected by MS. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519898340", "published_date": "2020-01-16T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 262133, "given_name": "Jennifer", "family_name": "McDonell", "ORCID": null, "country": null }, { "author_id": 241128, "given_name": "Kathleen", "family_name": "Costello", "ORCID": null, "country": null }, { "author_id": 179322, "given_name": "Joanna", "family_name": "Laurson-Doube", "ORCID": "http://orcid.org/0000-0001-9619-9170", "country": "GB" }, { "author_id": 262137, "given_name": "Nick", "family_name": "Rijke", "ORCID": null, "country": null }, { "author_id": 143429, "given_name": "Gavin", "family_name": "Giovannoni", "ORCID": "http://orcid.org/0000-0001-9995-1700", "country": null }, { "author_id": 241675, "given_name": "Brenda", "family_name": "Banwell", "ORCID": null, "country": null }, { "author_id": 224462, "given_name": "Peer", "family_name": "Baneke", "ORCID": "http://orcid.org/0000-0003-1271-4222", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "World Health Organization Essential Medicines List", "Multiple sclerosis disease-modifying therapies application" ], "doi": "10.1177/1352458519898340", "access": "open", "takeaways": " Multiple Sclerosis International Federation (MSIF) prepared an application for inclusion of MS disease-modifying therapies (DMTs) for the 2019 EML . Three DMTs were selected: glatiramer acetate, fingolimod, and ocrelizumab .", "categories": [] }, { "article_id": 380453, "title": "Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Planning pregnancy in patients with active multiple sclerosis (MS) is highly challenging because treatment withdrawn may be associated with dramatic disease reactivation. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To compare two strategies for women with active MS who were planning pregnancy: stopping natalizumab (1) at the end of the first trimester and (2) at conception. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Standardized strategy for women with active MS was initiated in our department. Maintenance of natalizumab until the end of first trimester was recommended (“secured first trimester” (SFT)). When patients refused, they were advised to continue until conception (“secured conception” (SC)). Predictors of disease activity during pregnancy were assessed. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Forty-six pregnancies were prospectively followed (30 with SFT and 16 with SC). One congenital anomaly occurred in the SC group. The proportions of patients with relapse and disability progression during pregnancy were lower in the SFT than in the SC group (3.6% vs 38.5%, p < 0.005 and 3.6% vs 30.8%, p < 0.05, respectively). Predictors of relapse and disability progression during pregnancy were the time when natalizumab was stopped (conception vs end of first trimester) and the number of relapses during the year before natalizumab. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Maintaining natalizumab during the first trimester may reduce the risk of disease reactivation during pregnancy in patients with active MS. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458520912637", "published_date": "2020-03-23T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 183844, "given_name": "Sarah", "family_name": "Demortiere", "ORCID": "http://orcid.org/0000-0002-8513-5443", "country": null }, { "author_id": 183845, "given_name": "Audrey", "family_name": "Rico", "ORCID": "http://orcid.org/0009-0002-5395-9963", "country": null }, { "author_id": 158971, "given_name": "Adil", "family_name": "Maarouf", "ORCID": "http://orcid.org/0000-0002-6755-496X", "country": null }, { "author_id": 244682, "given_name": "Clémence", "family_name": "Boutiere", "ORCID": null, "country": null }, { "author_id": 324605, "given_name": "Jean", "family_name": "Pelletier", "ORCID": "http://orcid.org/0000-0001-9730-7567", "country": null }, { "author_id": 158972, "given_name": "Bertrand", "family_name": "Audoin", "ORCID": "http://orcid.org/0000-0002-9860-7657", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Maintenance", "natalizumab", "the first trimester", "pregnancy", "active multiple sclerosis" ], "doi": "10.1177/1352458520912637", "access": "restricted", "takeaways": " Planning pregnancy in patients with active multiple sclerosis is challenging because treatment withdrawn may be associated with dramatic disease reactivation . Maintaining natalizumab during the first trimester may reduce the risk of relapse and disability progression during pregnancy .", "categories": [ { "category_id": 7, "category_description": "", "category_name": "Natalizumab", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ], "article_count": 298 } ] }, { "article_id": 380786, "title": "Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Mindfulness training is often used as a therapeutic intervention to manage stress and enhance emotional well-being, yet trials for multiple sclerosis (MS) are limited and few have used an active control. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> Assess the feasibility of mindfulness-based stress reduction (MBSR) for people with MS and evaluate the efficacy of MBSR compared to an education control. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We conducted a single-blind, randomized trial of MBSR versus education control among 62 adults with MS. Primary outcomes were measures of feasibility. Secondary outcomes included perceived stress, anxiety, depression, fatigue, pain, resilience, and the Paced Auditory Serial Addition Test, assessed at baseline, 8 weeks, and 12 months. Mean scores for secondary outcome measures were compared between groups at each time point and within groups across time by analyses of covariance or paired t-tests, respectively. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Successful recruitment and retention demonstrated feasibility. Improvements in several secondary outcomes were observed among both MBSR and control groups. However, differences between the groups were not statistically significant at either 8 weeks or 12 months. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Emotional well-being improved with both MBSR and education. Spontaneous improvement cannot be ruled out as an explanation for findings and additional studies that evaluate the impact of mindfulness training to improve emotional health are warranted. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518786650", "published_date": "2018-07-09T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 179576, "given_name": "Angela", "family_name": "Senders", "ORCID": "http://orcid.org/0000-0003-2507-4818", "country": null }, { "author_id": 246723, "given_name": "Douglas", "family_name": "Hanes", "ORCID": null, "country": null }, { "author_id": 154538, "given_name": "Dennis", "family_name": "Bourdette", "ORCID": "http://orcid.org/0000-0002-1312-8615", "country": null }, { "author_id": 278977, "given_name": "Kimberly", "family_name": "Carson", "ORCID": null, "country": null }, { "author_id": 278978, "given_name": "Lynn M", "family_name": "Marshall", "ORCID": null, "country": null }, { "author_id": 241129, "given_name": "Lynne", "family_name": "Shinto", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Impact", "mindfulness-based stress reduction", "people", "multiple sclerosis", "8 weeks", "12 months", "A randomized clinical trial" ], "doi": "10.1177/1352458518786650", "access": "open", "takeaways": " Mindfulness training is often used as a therapeutic intervention to manage stress and enhance emotional well-being . Trials for multiple sclerosis (MS) are limited and few have used an active control . We conducted a single-blind, randomized trial of MBSR versus education control among 62 adults with MS .", "categories": [] }, { "article_id": 382127, "title": "We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: Yes", "summary": "<jats:p> Proposal </jats:p><jats:p> Never underestimate the pervasive, powerful influence of constructive chaos in medical progress </jats:p>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458512440349", "published_date": "2012-05-22T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 268348, "given_name": "Neil", "family_name": "Scolding", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "We", "multiple sclerosis", "the next 10 years", "we", "its cause" ], "doi": "10.1177/1352458512446521", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 380557, "title": "Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate the significance of serum FAM19A5 in patients with NMOSD. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack ( p < 0.001) and number of past attacks ( p = 0.010) were independently associated with increased serum FAM19A5. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519885489", "published_date": "2019-11-04T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 280839, "given_name": "Hye Lim", "family_name": "Lee", "ORCID": null, "country": null }, { "author_id": 220203, "given_name": "Hung Youl", "family_name": "Seok", "ORCID": "http://orcid.org/0000-0002-9938-5355", "country": null }, { "author_id": 294660, "given_name": "Han-Wook", "family_name": "Ryu", "ORCID": null, "country": null }, { "author_id": 294661, "given_name": "Eun Bee", "family_name": "Cho", "ORCID": null, "country": null }, { "author_id": 294662, "given_name": "Bong Chul", "family_name": "Kim", "ORCID": null, "country": null }, { "author_id": 263407, "given_name": "Byoung Joon", "family_name": "Kim", "ORCID": null, "country": null }, { "author_id": 148913, "given_name": "Ju-Hong", "family_name": "Min", "ORCID": "http://orcid.org/0000-0002-7338-9067", "country": "KR" }, { "author_id": 268471, "given_name": "Jin Myoung", "family_name": "Seok", "ORCID": null, "country": null }, { "author_id": 148911, "given_name": "Ha Young", "family_name": "Shin", "ORCID": "http://orcid.org/0000-0002-4408-8265", "country": null }, { "author_id": 148919, "given_name": "Sa-Yoon", "family_name": "Kang", "ORCID": "http://orcid.org/0000-0001-6755-089X", "country": null }, { "author_id": 294667, "given_name": "Oh-Hyun", "family_name": "Kwon", "ORCID": null, "country": null }, { "author_id": 293992, "given_name": "Sang-Soo", "family_name": "Lee", "ORCID": null, "country": null }, { "author_id": 148920, "given_name": "Jeeyoung", "family_name": "Oh", "ORCID": "http://orcid.org/0000-0002-0378-2947", "country": "KR" }, { "author_id": 294670, "given_name": "Eun-Hee", "family_name": "Sohn", "ORCID": null, "country": null }, { "author_id": 148905, "given_name": "So-Young", "family_name": "Huh", "ORCID": "http://orcid.org/0000-0002-3309-6155", "country": null }, { "author_id": 243997, "given_name": "Joong-Yang", "family_name": "Cho", "ORCID": null, "country": null }, { "author_id": 294671, "given_name": "Jae Young", "family_name": "Seong", "ORCID": null, "country": null }, { "author_id": 174706, "given_name": "Byung-Jo", "family_name": "Kim", "ORCID": "http://orcid.org/0000-0002-0445-7185", "country": "KR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "FAM19A5", "neuromyelitis optica spectrum disorders", "it", "a new biomarker", "clinical status" ], "doi": "10.1177/1352458519885489", "access": "restricted", "takeaways": " FAM19A5 is involved in reactive gliosis, secreted by reactive astrocytes following central nervous system damage . Neuromyelitis optica spectrum disorder (NMOSD-AQP4) targets astrocetes and elevates levels of astrocalte-injury markers during attacks . Serum FAM19a5 levels were higher in patients with NMOSD with positive anti-aquaporin-4 antibody .", "categories": [] }, { "article_id": 380519, "title": "Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Multiple sclerosis (MS), is an emergent disease in Latin America (LATAM), which raises substantial socioeconomic challenges to a region where most countries remain as economies in development. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To assess barriers to access and utilization of MS care services in a regional cohort survey. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We conducted a cross-sectional study based on a self-reported survey. Patients with MS (PwMS) completed this regional survey in 12 Latin American (LATAM) countries. PwMS were also divided into those with healthcare insurance (including certain local national social security programs) and those without healthcare insurance (treated at public institutions). </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We surveyed 1469 PwMS and identified significant regional differences in relation to access to complementary tests, rehabilitation services, and prescription of disease-modifying therapies (DMTs). Between 44.4% and 73.5% of PwMS were unemployed and nearly 50% had completed higher education. PwMS receiving care from the private sector reported greater access to imaging, DMTs, and fewer problems obtaining DMTs compared to those treated at public institutions. Multivariate analysis showed that lack of private insurance (OR = 2.21, p < 0.001), longer MS duration (OR = 1.02, p = 0.001), lower level of education (OR = 0.66, p = 0.009), and unemployment (OR = 0.73, p = 0.03) were independently associated with inappropriate delivery of DMTs. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> These findings suggest barriers to access and utilization of MS care services across LATAM are prevalent. We identified several factors predicting unmet healthcare needs in PwMS. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519898590", "published_date": "2020-01-21T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 151200, "given_name": "Edgar", "family_name": "Carnero Contentti", "ORCID": "http://orcid.org/0000-0001-7435-5726", "country": "AR" }, { "author_id": 247659, "given_name": "Susana", "family_name": "Giachello", "ORCID": null, "country": null }, { "author_id": 151201, "given_name": "Jorge", "family_name": "Correale", "ORCID": "http://orcid.org/0000-0003-4756-9889", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Barriers", "utilization", "multiple sclerosis care services", "a large cohort", "Latin American patients" ], "doi": "10.1177/1352458519898590", "access": "open", "takeaways": " Multiple sclerosis (MS) is an emergent disease in Latin America (LATAM), which raises substantial socioeconomic challenges to a region where most countries remain as economies in development . We surveyed 1469 PwMS and identified significant regional differences in relation to access to complementary tests, rehabilitation services, and prescription of disease-modifying therapies (DMTs)", "categories": [] }, { "article_id": 380737, "title": "A healthy dietary pattern associates with a lower risk of a first clinical diagnosis of central nervous system demyelination", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> The evidence associating diet and risk of multiple sclerosis is inconclusive. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> We investigated associations between dietary patterns and risk of a first clinical diagnosis of central nervous system demyelination, a common precursor to multiple sclerosis. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We used data from the 2003–2006 Ausimmune Study, a case–control study examining environmental risk factors for a first clinical diagnosis of central nervous system demyelination, with participants matched on age, sex and study region. Using data from a food frequency questionnaire, dietary patterns were identified using principal component analysis. Conditional logistic regression models ( n = 698, 252 cases, 446 controls) were adjusted for history of infectious mononucleosis, serum 25-hydroxyvitamin D concentrations, smoking, race, education, body mass index and dietary misreporting. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We identified two major dietary patterns – healthy (high in poultry, fish, eggs, vegetables, legumes) and Western (high in meat, full-fat dairy; low in wholegrains, nuts, fresh fruit, low-fat dairy), explaining 9.3% and 7.5% of variability in diet, respectively. A one-standard deviation increase in the healthy pattern score was associated with a 25% reduced risk of a first clinical diagnosis of central nervous system demyelination (adjusted odds ratio 0.75; 95% confidence interval 0.60, 0.94; p = 0.011). There was no statistically significant association between the Western dietary pattern and risk of a first clinical diagnosis of central nervous system demyelination. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Following healthy eating guidelines may be beneficial for those at high risk of multiple sclerosis. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518793524", "published_date": "2018-08-07T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 272814, "given_name": "Lucinda J", "family_name": "Black", "ORCID": null, "country": null }, { "author_id": 281848, "given_name": "Charlotte", "family_name": "Rowley", "ORCID": null, "country": null }, { "author_id": 281849, "given_name": "Jill", "family_name": "Sherriff", "ORCID": null, "country": null }, { "author_id": 281850, "given_name": "Gavin", "family_name": "Pereira", "ORCID": null, "country": null }, { "author_id": 158960, "given_name": "Anne-Louise", "family_name": "Ponsonby", "ORCID": "http://orcid.org/0000-0002-6581-3657", "country": "AU" }, { "author_id": 265336, "given_name": "Robyn M", "family_name": "Lucas", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "A healthy dietary pattern associates", "a lower risk", "a first clinical diagnosis", "central nervous system demyelination" ], "doi": "10.1177/1352458518793524", "access": "open", "takeaways": " The evidence linking diet and risk of multiple sclerosis is inconclusive . We used data from the 2003–2006 Ausimmune Study to examine environmental risk factors for a first clinical diagnosis of central nervous system demyelination . Western dietary patterns explained 9.3% and 7.5% of variability in diet, respectively .", "categories": [] }, { "article_id": 380533, "title": "On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> The international standard to screen for cognitive impairment in multiple sclerosis (MS) is BICAMS (Brief International Cognitive Assessment for MS). However, with an application time of approximately 20 minutes, the battery might be too time consuming from a pragmatic perspective of a routine examination. </jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p> To examine the relative sensitivity and specificity of a BICAMS short version and its validity compared to the total battery. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> The German BICAMS version was applied comprising the Symbol Digit Modalities Test (SDMT), the Brief Visuospatial Memory Test–Revised (BVMT-R) and the Rey Auditory Verbal Learning Test (RAVLT; German VLMT). Single tests and two-test combinations were compared regarding conformity with the total battery. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Examining 1320 MS patients, the two-test combination of SDMT-BVMT-R was the most sensitive (92.7%) to impairment and showed the strongest agreement with the total battery (κ = 0.95). Performing binary logistic regression analyses, this combination was also validated by its association with employment status. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Application of the total BICAMS battery should be the goal to strive for. However, in time-restricted clinical settings, the combined application of SDMT and BVMT-R is a recommendable alternative with an application time of 10 minutes, while single tests alone are not sufficiently sensitive. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519887897", "published_date": "2019-11-19T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 282183, "given_name": "Sharon Jean", "family_name": "Baetge", "ORCID": null, "country": null }, { "author_id": 271242, "given_name": "Melanie", "family_name": "Filser", "ORCID": null, "country": null }, { "author_id": 282184, "given_name": "Alina", "family_name": "Renner", "ORCID": null, "country": null }, { "author_id": 282185, "given_name": "Sebastian", "family_name": "Ullrich", "ORCID": null, "country": null }, { "author_id": 246468, "given_name": "Christoph", "family_name": "Lassek", "ORCID": null, "country": null }, { "author_id": 147375, "given_name": "Iris-Katharina", "family_name": "Penner", "ORCID": "http://orcid.org/0000-0002-6746-1034", "country": "DE" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "the validity", "single tests", "the full Brief International Cognitive Assessment", "Multiple Sclerosis", "(BICAMS", "patients", "cognitive impairment" ], "doi": "10.1177/1352458519887897", "access": "restricted", "takeaways": " The international standard to screen for cognitive impairment in multiple sclerosis (MS) is BICAMS (Brief International Cognitive Assessment for MS) However, with an application time of approximately 20 minutes, the battery might be too time consuming from a pragmatic perspective of a routine examination . The two-test combination of SDMT-BVMT-R was the most sensitive to impairment .", "categories": [] }, { "article_id": 381316, "title": "Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Advanced magnetic resonance imaging (MRI) techniques provide a window into pathological processes in multiple sclerosis (MS). Nevertheless, to date only few studies have performed sodium MRI in MS. </jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p> We analysed total sodium concentration (TSC) in hyperacute, acute and chronic lesions in MS with <jats:sup>23</jats:sup>Na MRI. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> <jats:sup>23</jats:sup>Na MRI and <jats:sup>1</jats:sup>H MRI were performed in 65 MS patients and 10 healthy controls (HC). Mean TSC was quantified in all MS lesions with a diameter of >5 mm and in the normal appearing white and grey matter (NAWM, NAGM). </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> TSC in the NAWM and the NAGM of MS patients was significantly higher compared to HC (WM: 37.51 ± 2.65 mM versus 35.17 ± 3.40 mM; GM: 43.64 ± 2.75 mM versus 40.09 ± 4.64 mM). Acute and chronic MS lesions showed elevated TSC levels of different extent (contrast-enhancing lesions (49.07 ± 6.99 mM), T1 hypointense lesions (45.06 ± 6.26 mM) and remaining T1 isointense lesions (39.88 ± 5.54 mM)). However, non-enhancing hyperacute lesions with a reduced apparent diffusion coefficient showed a TSC comparable to the NAWM (37.22 ± 4.62 mM). </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> TSC is not only a sensitive marker of the severity of chronic tissue abnormalities in MS but is also highly sensitive to opening of the blood–brain barrier and vasogenic tissue oedema in contrast-enhancing lesions. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/10.1177/1352458515609430", "published_date": "2015-10-09T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 166198, "given_name": "Philipp", "family_name": "Eisele", "ORCID": "http://orcid.org/0000-0001-6831-4282", "country": null }, { "author_id": 282207, "given_name": "Simon", "family_name": "Konstandin", "ORCID": null, "country": null }, { "author_id": 282209, "given_name": "Martin", "family_name": "Griebe", "ORCID": null, "country": null }, { "author_id": 282211, "given_name": "Kristina", "family_name": "Szabo", "ORCID": null, "country": null }, { "author_id": 282212, "given_name": "Marc E", "family_name": "Wolf", "ORCID": null, "country": null }, { "author_id": 282213, "given_name": "Angelika", "family_name": "Alonso", "ORCID": null, "country": null }, { "author_id": 250514, "given_name": "Anne", "family_name": "Ebert", "ORCID": null, "country": null }, { "author_id": 282214, "given_name": "Julia", "family_name": "Serwane", "ORCID": null, "country": null }, { "author_id": 282215, "given_name": "Christina", "family_name": "Rossmanith", "ORCID": null, "country": null }, { "author_id": 282216, "given_name": "Michael G", "family_name": "Hennerici", "ORCID": null, "country": null }, { "author_id": 282217, "given_name": "Lothar R", "family_name": "Schad", "ORCID": null, "country": null }, { "author_id": 168611, "given_name": "Achim", "family_name": "Gass", "ORCID": "http://orcid.org/0000-0003-0294-2555", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Heterogeneity", "acute multiple sclerosis lesions", "sodium", "(23Na) MRI" ], "doi": "10.1177/1352458515609430", "access": "restricted", "takeaways": " Total sodium concentration (TSC) in hyperacute, acute and chronic lesions in MS was significantly higher compared to HC . Acute and chronic MS lesions showed elevated TSC levels of different extent . TSC is also highly sensitive to opening of the blood–brain barrier and vasogenic tissue oedema in contrast-enhancing lesions .", "categories": [] } ] }